Prospective Phase I Trial of Concurrent Full Dose Gemcitabine/Nab-paclitaxel and Ablative Radiation Therapy for Borderline and Locally Advanced Pancreatic Cancer

被引：0
|
作者：
Kim, H. [1 ]
Olsen, J. R. [2 ]
Wang-Gillam, A. [3 ]
Green, O. L. [1 ]
Fields, R. C. [4 ]
Hammill, C. [4 ]
Strasberg, S. [4 ]
Doyle, M. B. [4 ]
Hawkins, W. [4 ]
Suresh, R. [5 ]
Tan, B. [5 ]
Pedersen, K. [5 ]
Henke, L. E. [1 ]
DeWees, T. A. [6 ]
Chapman, W. [4 ]
Parikh, P. J. [7 ]
Roach, M. C., Jr. [1 ]
机构：
[1] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, CO USA
[3] Washington Univ, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Med, Div Hematol Oncol, St Louis, MO 63110 USA
[6] Mayo Clin, Dept Biomed Informat, Scottsdale, AZ USA
[7] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1203
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [31] Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
    Mahipal, Amit
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Goyal, Gaurav
    Soares, Heloisa
    Neuger, Anthony
    Copolla, Domenico
    Kim, Jongphil
    Kim, Richard
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 473 - 481
  • [32] Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
    Amit Mahipal
    Sri Harsha Tella
    Anuhya Kommalapati
    Gaurav Goyal
    Heloisa Soares
    Anthony Neuger
    Domenico Copolla
    Jongphil Kim
    Richard Kim
    Investigational New Drugs, 2019, 37 : 473 - 481
  • [33] Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine
    Allen, AM
    Zalupski, MM
    Robertson, JM
    Eckhauser, FE
    Simone, D
    Brown, D
    Hejna, G
    Normolle, D
    Lawrence, TS
    McGinn, CJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1461 - 1467
  • [34] Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Al-Toubah, Taymeyah E.
    Kim, Richard D.
    Kim, Jongphil
    Lewis, Neron K.
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [35] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Springett, Gregory M.
    Kim, Richard D.
    Williams-Elson, Irene
    Miller, Kara
    Kothari, Nishi
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.
    Gupta, Niraj K.
    Singh, Kirpal
    Glass, Timothy
    Davis, Chad
    Lybik, Mark
    Leagre, Christopher
    Liebross, Robert H.
    Dugan, Thomas
    Edwards, Mark
    Givens, Stanley
    Compton, Julia
    Tigges, Thomas
    Flanders, Vincent
    Mathavan, Vinay
    Isch, Andrew
    Reeves, Dave
    Arevalo, Gabriel
    Rowe, Michael
    Kaderabek, Douglas
    Arregui, Maurice
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
    Sueyoshi, Hironari
    Ioka, Tatsuya
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [39] Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
    McGinn, CJ
    Zalupski, MM
    Shureiqi, I
    Robertson, JM
    Eckhauser, FE
    Smith, DC
    Brown, D
    Hejna, G
    Strawderman, M
    Normolle, D
    Lawrence, TS
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4202 - 4208
  • [40] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Neuger, Anthony
    Almhanna, Khaldoun
    Wapinsky, Georgine
    Bertels, Barbara
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345